Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.

Cancer
Kimmo PorkkaJorge E Cortes

Abstract

Dasatinib, a highly potent BCR-ABL inhibitor, is an effective treatment for patients with chronic myeloid leukemia in chronic phase (CML CP) after resistance, suboptimal response, or intolerance to prior imatinib. In a phase 3 dose optimization trial in patients with CML CP (CA180-034), the occurrence of pleural effusion was significantly minimized with dasatinib 100 mg once daily (QD) compared with other treatment arms (70 mg twice daily [twice daily], 140 mg QD, or 50 mg twice daily). To investigate the occurrence and management of pleural effusion during dasatinib treatment, and efficacy in patients with or without pleural effusion, data from CA180-034 were analyzed. With 24-month minimum follow-up, 14% of patients treated with dasatinib 100 mg QD incurred pleural effusion (grade 3: 2%; grade 4: 0%) compared with 23% to 26% in other study arms. The pleural effusion rate showed only a minimal increment from 12 to 24 months. In the 100 mg QD study arm, median time to pleural effusion (any grade) was 315 days, and after pleural effusion, 52% of patients had a transient dose interruption, 35% had a dose reduction, 57% received a diuretic, and 26% received a corticosteroid. Three patients in the 100 mg QD study arm discontinued t...Continue Reading

References

Jun 30, 2007·American Journal of Respiratory and Critical Care Medicine·Anne BergeronPhilippe Rousselot
Sep 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alfonso Quintás-CardamaJorge Cortes
Jun 11, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil P ShahAndreas Hochhaus

❮ Previous
Next ❯

Citations

Aug 15, 2013·Journal of Cancer Research and Clinical Oncology·Andreas Hochhaus, Hagop Kantarjian
Feb 6, 2013·Current Hematologic Malignancy Reports·David Marin
Apr 21, 2010·International Journal of Hematology·Yasunobu NagataHisashi Sakamaki
Jun 8, 2010·The New England Journal of Medicine·Hagop KantarjianMichele Baccarani
Apr 9, 2010·Current Opinion in Pulmonary Medicine·Anupama G Brixey, Richard W Light
Dec 14, 2011·The Cancer Journal·David W WoessnerMichael W Deininger
Dec 24, 2010·Journal of Virology·Elena E GorbunovaErich R Mackow
Jul 20, 2012·Advances in Virology·Irina GavrilovskayaErich Mackow
Apr 21, 2011·Current Oncology·S Assouline, J H Lipton
Sep 18, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Elisabetta AbruzzeseRoberto Latagliata
Jul 27, 2014·Current Opinion in Virology·Nadine A Dalrymple, Erich R Mackow
Oct 3, 2014·Case Reports in Medicine·Hava Usküdar TekeNeslihan Andıç
Jul 6, 2012·Leukemia & Lymphoma·Beverly Bethelmie-BryanHanna Jean Khoury
Jan 7, 2016·Drug Metabolism and Pharmacokinetics·Masatomo Miura, Naoto Takahashi
Mar 21, 2012·Expert Opinion on Pharmacotherapy·Maria Florencia TanakaElias Jabbour
Nov 12, 2013·Critical Reviews in Oncology/hematology·Semra Paydas
Jan 16, 2016·American Journal of Hematology·Elias Jabbour
Sep 19, 2012·American Journal of Hematology·Philippe RousselotUNKNOWN French Intergroup For Chronic Myelogenous Leukemia (Fi-LMC)
Feb 13, 2014·Hematological Oncology·Rong-Tai CuiChuan-Qiang Pu
Aug 15, 2015·Journal of Voice : Official Journal of the Voice Foundation·Sharon Ovnat TamirTal Marom
Apr 5, 2015·Expert Opinion on Pharmacotherapy·Morgan L MaceElias J Jabbour
May 30, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Michel ZwaanPamela R Kearns
Jun 25, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jagoda K Jasielec, Richard A Larson
Jan 16, 2018·British Journal of Clinical Pharmacology·Nurgül Özgür Yurttaş, Ahmet Emre Eşkazan
Jul 29, 2017·The European Respiratory Journal·Jason WeatheraldDavid Montani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.